Novo Holdings Leads €7M Seed Investment in Bactolife
April 20, 2021
Novo Holdings (via its Novo Seeds team) led a €7 million seed round in Danish biotech Bactolife, committing €5 million to advance the company's pipeline. The funding will support development and scaling of Bactolife's anti-virulence Virulence Inactivating Proteins (VIPs) for animal and human gut health; Novo's Aleks Engel will join Bactolife's board.
- Buyers
- Novo Holdings (Novo Seeds)
- Targets
- Bactolife
- Industry
- Biotechnology
- Location
- Denmark
- Transaction Type
- Growth capital
Explore More
Related Acquisitions
-
Novo Holdings to Acquire Benchmark Genetics
November 25, 2024
Biotechnology
Novo Holdings agreed to acquire Benchmark Genetics from Benchmark Holdings plc for an enterprise value of up to £260 million. Completion is expected in the first quarter of 2025, subject to shareholder approval and regulatory clearances, with initial consideration of £230 million plus up to £30 million contingent on revenue thresholds.
-
Novo Holdings Invests £50m in Oxford Nanopore Technologies
August 1, 2024
Biotechnology
Novo Holdings has invested £50 million in UK-listed Oxford Nanopore Technologies via an equity issue and intends to make further share purchases in the secondary market. The investment is intended to support Oxford Nanopore's commercial growth and capability expansion in biopharmaceutical and biomanufacturing markets.
-
Novo Holdings Acquires 25% Stake in Sejet Plant Breeding
June 27, 2024
Agriculture
Novo Holdings has agreed to acquire a 25% minority stake in Sejet Plant Breeding from DLG Group. The partnership will provide growth capital to scale Sejet’s plant-breeding operations and invest in new genomic and breeding technologies to accelerate development of climate-resilient crop varieties.
-
Novo Holdings Invests $40M in Evosep
January 9, 2023
Biotechnology
Novo Holdings has invested $40 million in Evosep to accelerate the commercialization and clinical application of Evosep’s standardized proteomics liquid chromatography platform. The funds will support product development and global expansion — particularly into the U.S. — and Novo Holdings’ principal, Stephen Van Helden, will join Evosep’s board.
-
Novo Holdings Invests $72 Million in LanzaTech
August 6, 2019
Biotechnology
Novo Holdings A/S made a $72 million Series E growth equity investment in LanzaTech to support expansion and commercialization of the company's carbon-recycling fuels and chemicals platform. Anders Bendsen Spohr of Novo Holdings will join LanzaTech's board as the investment aims to accelerate deployment of LanzaTech's sustainable fuels, chemicals and polyethylene produced from recycled carbon.
-
Novo Holdings Invests in Oxford Biomedica plc
May 28, 2019
Biotechnology
Novo Holdings A/S agreed to invest up to £53.5 million in new ordinary shares of Oxford Biomedica plc, taking up to a 10.1% stake. The proceeds will be used to repay an existing Oaktree debt facility in full and to scale Oxford Biomedica's LentiVector platform and proprietary product portfolio.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.